The board of directors of Shanghai Junshi Biosciences Co., Ltd. announce that the Company and Wuxi Runmin Pharmaceutical Technology Co., Ltd."Wuxi Runmin", a subsidiary controlled by the Company, received the Acceptance Notice issued by the National Medical Products Administration. The investigational new drug application for the JS401 injection has been accepted. Each of the Company and Risen (Shanghai) Medical Technology Co., Ltd. own 50% shareholdings in Wuxi Runmin, respectively.

Relevant information is as follows: Drug name: JS401 injection Application matter: Clinical Trial of Domestic Production Registration of Pharmaceutical Product Acceptance No.: CXHL2300136 Applicant: Shanghai Junshi Biosciences Co., Ltd. Wuxi Runmin Pharmaceutical Technology Co., Ltd. Review conclusion: Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China. JS401 is a small interfering RNA drug targeting angiopoietin-like protein 3 ("ANGPTL3") messenger RNA ("mRNA") jointly developed by the Company and its partner Risen Shanghai, which is intended to be mainly used for the treatment of hyperlipidemia and other treatments. ANGPTL3 is a member of the angiopoietin-like protein family expressed by the liver that regulates lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL).

Loss-of-function or inhibition of ANGPTL3 can significantly reduce the levels of triglycerides and other atherogenic lipoproteins. JS401 is delivered into hepatocytes through N-acetylgalactosamine (GalNac), where it specifically degrades ANGPTL3 mRNA and continuously inhibits the expression of ANGPTL3 protein, thereby exerting its lipid-lowering effect on triglycerides and cholesterol. As of the date of this announcement, there is only one monoclonal antibody drug Evkeeza (Evinacumab-dgnb, a product of Regeneron) targeting ANGPTL3 approved in the world for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH), and no similar target siRNA product has been approved for marketing globally.

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Such stages are susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development project and fulfil its information disclosure obligations in a timely manner for subsequent progress in strict compliance with relevant regulations.